Menu

Pfizer CEO Albert Bourla told investors that "340B reform is something that myself and the entire pharma [industry] is setting as a priority."

Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue

October 31, 2024 William Newton, Associate Editor/Senior Writer Views

Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

William Newton